BTIG Reiterates Buy Rating on Rocket Pharmaceuticals (RCKT), Defending on Weakness
Tweet Send to a Friend
BTIG analyst Yun Zhong reiterated a Buy rating and $35.00 price target on Rocket Pharmaceuticals (NASDAQ: RCKT).The analyst comments "We ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
